Fluorocytosine
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2011 (NCT04327011)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- cytosine permeaseINHIBITOR
cytosine permease inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04195373 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2020 | Assign Clinical Research GmbH, SSS International Clinical Research GmBH, Themis Bioscience GmbH, University of Tuebingen |
| NCT04327011 | Phase 1 | Feb 28, 2011 | The Cleveland Clinic, Tocagen Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Assign Clinical Research GmbH | For profit | 1 | 0 | 1 | 2020 |
| SSS International Clinical Research GmBH | For profit | 1 | 0 | 1 | 2020 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Themis Bioscience GmbH | For profit | 1 | 1 | 1 | 2020 |
| Tocagen Inc. | For profit | 1 | 1 | 1 | 2011 |
| University of Tuebingen | Academic/Hospital | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1